Toxoplasmosis

Organism/Life Cycle

Toxoplasma gondii — obligate intracellular protozoan. Definitive host: CATS (felids) only — full sexual/coccidian cycle → OOCYSTS shed in feces (environmentally resistant). Intermediate hosts: ALL warm-blooded animals incl. humans — asexual reproduction only → TISSUE CYSTS (bradyzoites), persist lifelong in muscle, cardiac, CNS/brain.

Transmission

Oocysts: soil/water/produce contaminated by cat feces
Tissue cysts: UNDERCOOKED MEAT (commonly tested route)
Transplacental (acute maternal infection) — see Congenital Toxoplasmosis topic separately

Immune Status Determines Clinical Significance (like Cryptococcosis/PML/PCP pattern)

Immunocompetent primary infection: asymptomatic or mild self-limited (± mono-like syndrome, lymphadenopathy) → LIFELONG LATENT infection (tissue cysts), controlled by intact CMI. Toxoplasmic encephalitis = REACTIVATION of latent cysts under immunosuppression. Classic context: advanced HIV/AIDS, CD4 <100 (KEY NUMBER — lower than PCP’s CD4<200, marks even MORE advanced immunosuppression). AIDS-defining illness (like PCP, cryptococcal meningitis).

Clinical

Headache, fever, focal neuro deficits (from MULTIPLE FOCAL MASS LESIONS — not diffuse meningoencephalitis pattern), altered mentation, seizures common. KEY DIFFERENTIAL: Primary CNS Lymphoma — both present as multiple ring-enhancing lesions in same advanced-HIV population. High-yield diagnostic dilemma.

Diagnosis

CT/MRI: MULTIPLE RING-ENHANCING lesions, predilection basal ganglia.

Positive Toxoplasma IgG serology (indicates latent infection — prerequisite for reactivation). → Often sufficient for PRESUMPTIVE DIAGNOSIS + EMPIRICAL TREATMENT TRIAL (distinctive approach — not biopsy-first). Brain biopsy RESERVED for treatment NON-RESPONDERS (~1-2wk trial) — non-response raises suspicion for CNS lymphoma needing histology. “Treat first, biopsy only failures” — testable, distinct from usual biopsy/culture-first approach to CNS mass lesions.

Treatment

Pyrimethamine + sulfadiazine + FOLINIC ACID (mitigates pyrimethamine-induced bone marrow suppression — antifolate/DHFR inhibition mechanism, see AMR topic) = standard 1st-line. Clindamycin + pyrimethamine = alternative (sulfa allergy). Secondary prophylaxis/maintenance continued until sustained CD4 recovery on ART — same “restore host CMI = durable control” principle as cryptococcal meningitis/PCP.

The Organism and Its Genuinely Distinctive Life Cycle

Toxoplasma gondii is an obligate intracellular protozoan parasite with a genuinely distinctive life cycle worth understanding in structural detail, since it directly explains both the parasite’s remarkably broad host range and its two principal clinically important human disease contexts (covered here and, separately, under Congenital Toxoplasmosis). Cats (felids) are the definitive host — the only host in which the parasite’s full sexual (coccidian) life cycle occurs, producing environmentally resistant oocysts shed in cat faeces — while essentially all warm-blooded animals, including humans, serve as intermediate hosts, in which the parasite reproduces only asexually, forming tissue cysts (containing slowly dividing bradyzoites) that persist, generally lifelong, in tissues including skeletal muscle, cardiac muscle, and, genuinely importantly for this topic, the CNS/brain.

Transmission

Humans acquire infection through several genuinely distinct routes: ingesting oocysts from soil, water, or unwashed produce contaminated by cat faeces; ingesting tissue cysts in undercooked meat (a genuinely important, commonly tested transmission route, given how widely tissue cysts are distributed across intermediate-host animal species used for food); and, covered specifically under Congenital Toxoplasmosis, transplacental transmission from an acutely infected pregnant mother to the fetus.

Immune Status as the Central Determinant — The Organizing Principle for This Topic

As with several other organisms covered across this CNS section (cryptococcosis, PML, PCP), Toxoplasma’s clinical significance in this particular topic is overwhelmingly determined by host cell-mediated immune status, and this dependence is genuinely the single most important organizing concept here: primary infection in an immunocompetent host is typically asymptomatic or causes only a mild, self-limited illness (occasionally a mononucleosis-like syndrome with lymphadenopathy), after which the parasite establishes lifelong latent infection via tissue cysts, held in check indefinitely by intact CMI — genuinely analogous in this latency-and-reactivation-on-immunosuppression logic to several herpesvirus and JC virus (PML) patterns covered elsewhere, though the specific organism and mechanism differ. Toxoplasmic encephalitis, the clinically dominant CNS manifestation, occurs specifically from reactivation of latent tissue cysts in the setting of significant immunosuppression — most classically advanced HIV/AIDS with a CD4 count below 100 (a genuinely important, specific numeric threshold worth remembering, lower than the CD4<200 threshold associated with PCP, reflecting toxoplasmic encephalitis’s status as a marker of even more advanced immunosuppression) — making toxoplasmic encephalitis, like PCP and cryptococcal meningitis, a classic AIDS-defining illness.

Clinical Manifestations

Toxoplasmic encephalitis presents with headache, fever, focal neurological deficits (reflecting the disease’s characteristic tendency to form multiple, focal mass lesions within the brain, rather than a diffuse meningoencephalitic picture), altered mental status, and, in a substantial proportion, seizures — the focal, mass-lesion pattern is genuinely, specifically important because it drives a real, frequently tested differential diagnosis challenge in the HIV-positive patient: distinguishing toxoplasmic encephalitis from primary CNS lymphoma, since both present with focal, often multiple, ring-enhancing mass lesions on neuroimaging in the same at-risk (advanced HIV) population, a genuinely important, specifically testable diagnostic dilemma with real management consequences (below).

Diagnosis

Neuroimaging (CT or, preferably, MRI) classically shows multiple ring-enhancing lesions, often with a predilection for the basal ganglia — this imaging pattern, combined with positive Toxoplasma IgG serology (indicating prior exposure/latent infection, essentially a prerequisite for reactivation disease, since reactivation cannot occur without pre-existing latent infection) in the appropriate advanced-immunosuppression clinical context, is often sufficient to support a presumptive diagnosis and empirical treatment trial — a genuinely important, practical diagnostic approach distinctive to this topic: rather than mandating brain biopsy (an invasive procedure with real risk) before treatment, clinical practice commonly proceeds directly to empirical anti-Toxoplasma therapy, reserving brain biopsy specifically for cases that fail to respond clinically/radiologically within roughly 1-2 weeks of appropriate treatment — since a lack of expected treatment response is precisely what should raise suspicion for the alternative diagnosis, primary CNS lymphoma, needing histological confirmation. This “treat first, biopsy only non-responders” approach is a genuinely distinctive, specifically testable diagnostic strategy worth remembering as different from the more universally biopsy/culture-first approach used for most other CNS mass lesions.

Treatment

Pyrimethamine plus sulfadiazine (with folinic acid supplementation to mitigate pyrimethamine’s dose-limiting bone marrow suppression, since pyrimethamine inhibits dihydrofolate reductase — the same general antifolate mechanism logic covered under Antimicrobial Agents and Antimicrobial Resistance, here applied against a protozoan target) is the standard, first-line treatment regimen; clindamycin plus pyrimethamine serves as an alternative regimen for patients with genuine sulfa allergy. As with the other CD4-dependent opportunistic CNS infections covered in this section (cryptococcal meningitis, PCP), secondary prophylaxis (maintenance therapy) is continued after acute treatment until sustained CD4 recovery on effective antiretroviral therapy allows safe discontinuation, again illustrating the recurring principle that durable control ultimately depends on restoring host CMI rather than antimicrobial treatment of the organism alone.